Monoclonal antibody strategies to block angiogenesis

Daniel J. Hicklin, Larry Witte, Zhenping Zhu, Francesca-Fang Liao, Yan Wu, Yiwen Li, Peter Bohlen

Research output: Contribution to journalReview article

66 Citations (Scopus)

Abstract

Antibodies represent a unique class of therapeutics because of their high specificity towards a defined target antigen. Recent clinical success with antibody-based cancer therapeutics has led to an increase in the clinical development of these agents. Antibody therapeutics offer a promising approach for inhibiting new blood vessel formation (angiogenesis), which is associated with a variety of diseases, including cancer. In this review we will focus on angiogenesis-related mechanisms targeted by antibody-based therapeutics, with an emphasis on those studies where pre-clinical in vivo data is available.

Original languageEnglish (US)
Pages (from-to)517-528
Number of pages12
JournalDrug Discovery Today
Volume6
Issue number10
DOIs
StatePublished - May 15 2001

Fingerprint

Monoclonal Antibodies
Antibodies
Therapeutics
Blood Vessels
Neoplasms
Antigens

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

Hicklin, D. J., Witte, L., Zhu, Z., Liao, F-F., Wu, Y., Li, Y., & Bohlen, P. (2001). Monoclonal antibody strategies to block angiogenesis. Drug Discovery Today, 6(10), 517-528. https://doi.org/10.1016/S1359-6446(01)01759-7

Monoclonal antibody strategies to block angiogenesis. / Hicklin, Daniel J.; Witte, Larry; Zhu, Zhenping; Liao, Francesca-Fang; Wu, Yan; Li, Yiwen; Bohlen, Peter.

In: Drug Discovery Today, Vol. 6, No. 10, 15.05.2001, p. 517-528.

Research output: Contribution to journalReview article

Hicklin, DJ, Witte, L, Zhu, Z, Liao, F-F, Wu, Y, Li, Y & Bohlen, P 2001, 'Monoclonal antibody strategies to block angiogenesis', Drug Discovery Today, vol. 6, no. 10, pp. 517-528. https://doi.org/10.1016/S1359-6446(01)01759-7
Hicklin, Daniel J. ; Witte, Larry ; Zhu, Zhenping ; Liao, Francesca-Fang ; Wu, Yan ; Li, Yiwen ; Bohlen, Peter. / Monoclonal antibody strategies to block angiogenesis. In: Drug Discovery Today. 2001 ; Vol. 6, No. 10. pp. 517-528.
@article{aeeed17495d94daf86915bf8f0978de3,
title = "Monoclonal antibody strategies to block angiogenesis",
abstract = "Antibodies represent a unique class of therapeutics because of their high specificity towards a defined target antigen. Recent clinical success with antibody-based cancer therapeutics has led to an increase in the clinical development of these agents. Antibody therapeutics offer a promising approach for inhibiting new blood vessel formation (angiogenesis), which is associated with a variety of diseases, including cancer. In this review we will focus on angiogenesis-related mechanisms targeted by antibody-based therapeutics, with an emphasis on those studies where pre-clinical in vivo data is available.",
author = "Hicklin, {Daniel J.} and Larry Witte and Zhenping Zhu and Francesca-Fang Liao and Yan Wu and Yiwen Li and Peter Bohlen",
year = "2001",
month = "5",
day = "15",
doi = "10.1016/S1359-6446(01)01759-7",
language = "English (US)",
volume = "6",
pages = "517--528",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Monoclonal antibody strategies to block angiogenesis

AU - Hicklin, Daniel J.

AU - Witte, Larry

AU - Zhu, Zhenping

AU - Liao, Francesca-Fang

AU - Wu, Yan

AU - Li, Yiwen

AU - Bohlen, Peter

PY - 2001/5/15

Y1 - 2001/5/15

N2 - Antibodies represent a unique class of therapeutics because of their high specificity towards a defined target antigen. Recent clinical success with antibody-based cancer therapeutics has led to an increase in the clinical development of these agents. Antibody therapeutics offer a promising approach for inhibiting new blood vessel formation (angiogenesis), which is associated with a variety of diseases, including cancer. In this review we will focus on angiogenesis-related mechanisms targeted by antibody-based therapeutics, with an emphasis on those studies where pre-clinical in vivo data is available.

AB - Antibodies represent a unique class of therapeutics because of their high specificity towards a defined target antigen. Recent clinical success with antibody-based cancer therapeutics has led to an increase in the clinical development of these agents. Antibody therapeutics offer a promising approach for inhibiting new blood vessel formation (angiogenesis), which is associated with a variety of diseases, including cancer. In this review we will focus on angiogenesis-related mechanisms targeted by antibody-based therapeutics, with an emphasis on those studies where pre-clinical in vivo data is available.

UR - http://www.scopus.com/inward/record.url?scp=0035336732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035336732&partnerID=8YFLogxK

U2 - 10.1016/S1359-6446(01)01759-7

DO - 10.1016/S1359-6446(01)01759-7

M3 - Review article

VL - 6

SP - 517

EP - 528

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 10

ER -